Sugi Predict

Sugi Predict / Compounds / SCHEMBL6584559

SCHEMBL6584559

SCHEMBL6584559

Brc1cccc2c1CCCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 1/20 0.39
▸ ICAM1 P05362 1/20 0.39
▸ ITGAL P20701 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ CRHBP P24387 2/20 0.35
▸ CRHR2 Q13324 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ MTNR1A P48039 1/20 0.35
▸ MTNR1B P49286 1/20 0.35
▸ HTR2A P28223 7/20 0.35
▸ HTR2C P28335 7/20 0.35
▸ HTR2B P41595 6/20 0.35
▸ HTR1A P08908 5/20 0.35
▸ HTR1D P28221 4/20 0.35
▸ ACHE P22303 2/20 0.33
▸ PARP10 Q53GL7 1/20 0.33
▸ PARP11 Q9NR21 1/20 0.33
▸ MAP3K14 Q99558 1/20 0.33
▸ DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31394887 1.00 ITGB2 (0.39) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2829908 0.88 ITGB2 (0.42) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL436160 0.78 MAP3K14 (0.46) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL31598947 0.76 BCL2L1 (0.48) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2481284 0.76 ACHE (0.40) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL5673196 0.76 BCL2L1 (0.48) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL29509471 0.76 ACHE (0.40) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL139722 0.76 ACHE (0.45) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL20870690 0.76 ITGB2 (0.39) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL14616764 0.76 ACHE (0.45) ITGB2ICAM1ITGALSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 — — US disclosed
CN-112004816-B PRC2 inhibitors 米拉蒂医疗股份有限公司 2024-01-05 — — CN disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 — — EP disclosed
CN-116981661-A Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2023-10-31 — — CN disclosed
CN-116648452-A Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof 上海科州药物研发有限公司 2023-08-25 — — CN disclosed
CN-116194456-A Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof 上海科州药物研发有限公司 2023-05-30 — — CN disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 — — US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 — — CN disclosed
EP-3980422-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER Mirati Therapeutics, Inc. (US) 2022-04-13 — — EP disclosed
CN-114269748-A Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer 米拉蒂医疗股份有限公司 2022-04-01 — — CN disclosed
EP-3959214-A1 NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-02 — — EP disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 — — EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 — — CN disclosed
CN-112004816-A PRC2 inhibitors 米拉蒂医疗股份有限公司 2020-11-27 — — CN disclosed
EP-1189900-B1 HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES AS MELATONERGIC AGENTS BRISTOL MYERS SQUIBB CO (US) 2004-01-14 — — EP disclosed
EP-1189900-A4 HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES AS MELATONERGIC AGENTS BRISTOL MYERS SQUIBB CO (US) 2002-07-31 — — EP disclosed
EP-1189900-A1 HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES AS MELATONERGIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-27 — — EP disclosed
US-6211225-B1 SLEEP DISORDERS AND CIRCADIAN RHYTHM DISORDERS BRISTOL-MEYERS SQUIBB 2001-04-03 — — US disclosed
WO-2001002392-A1 HETEROCYCLIC AMINOPYRROLIDINE DERIVATIVES AS MELATONERGIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 ITGB2 4862/4885ICAM1 3527/4885ITGAL 4817/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 ITGB2 4862/4885ICAM1 3527/4885ITGAL 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.